EVOK
Income statement / Annual
Last year (2024), Evoke Pharma, Inc.'s total revenue was $10.25 M,
an increase of 97.84% from the previous year.
In 2024, Evoke Pharma, Inc.'s net income was -$5.35 M.
See Evoke Pharma, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$10.25 M |
$5.18 M |
$2.51 M |
$1.62 M |
$23.02 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$356.53 K
|
$201.88 K
|
$370.39 K
|
$328.12 K
|
$86.71 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$9.89 M
|
$4.98 M
|
$2.14 M
|
$1.29 M
|
-$63.69 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0.97
|
0.96
|
0.85
|
0.8
|
-2.77
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$16.32 K
|
$181.91 K
|
$300.79 K
|
$590.48 K
|
$6.55 M
|
$3.42 M
|
$4.10 M
|
$7.14 M
|
$6.95 M
|
$8.15 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$3.92 M
|
$4.09 M
|
$3.59 M
|
$3.66 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$15.08 M
|
$12.23 M
|
$9.62 M
|
$8.85 M
|
$6.43 M
|
$3.74 M
|
$3.92 M
|
$4.09 M
|
$3.59 M
|
$3.66 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$15.10 M
|
$12.41 M
|
$9.92 M
|
$9.44 M
|
$12.98 M
|
$7.15 M
|
$8.01 M
|
$11.23 M
|
$10.54 M
|
$11.82 M
|
| Cost And Expenses |
$15.45 M
|
$12.61 M
|
$10.29 M
|
$9.77 M
|
$13.07 M
|
$7.15 M
|
$8.01 M
|
$11.23 M
|
$10.54 M
|
$11.82 M
|
| Interest Income |
$353.31 K
|
$138.60 K
|
$62.01 K
|
$8.62 K
|
$5.67 K
|
$28.80 K
|
$15.21 K
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$501.37 K
|
$500.00 K
|
$500.00 K
|
$500.05 K
|
$112.99 K
|
$0.00
|
$15.21 K
|
$6.52 K
|
$268.03 K
|
$0.00
|
| Depreciation & Amortization |
$5.20 M
|
$138.60 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$8.01 M
|
$11.23 M
|
$10.54 M
|
$303.16 K
|
| EBITDA |
$353.31 K |
-$7.15 M |
-$7.72 M |
-$8.04 M |
-$13.04 M |
-$7.13 M |
$0.00 |
$0.00 |
$0.00 |
-$11.52 M |
| EBITDA Ratio |
0.03
|
-1.38
|
-3.08
|
-4.97
|
-566.54
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.51
|
-1.43
|
-3.1
|
-5.04
|
-566.78
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$148.06 K
|
-$361.40 K
|
-$437.99 K
|
-$386.31 K
|
-$107.32 K
|
$28.80 K
|
$448.61 K
|
-$998.83 K
|
-$204.11 K
|
-$303.16 K
|
| Income Before Tax |
-$5.35 M
|
-$7.79 M
|
-$8.22 M
|
-$8.54 M
|
-$13.15 M
|
-$7.13 M
|
-$7.57 M
|
-$12.23 M
|
-$10.75 M
|
-$12.12 M
|
| Income Before Tax Ratio |
-0.52
|
-1.5
|
-3.28
|
-5.28
|
-571.45
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$6.52 K
|
$0.00
|
$0.00
|
| Net Income |
-$5.35 M
|
-$7.79 M
|
-$8.22 M
|
-$8.54 M
|
-$13.15 M
|
-$7.13 M
|
-$7.57 M
|
-$12.23 M
|
-$10.75 M
|
-$12.12 M
|
| Net Income Ratio |
-0.52
|
-1.5
|
-3.28
|
-5.28
|
-571.45
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-2.81 |
-27.97 |
-31.16 |
-40.4 |
-74.91 |
-45.84 |
-65.62 |
-118.21 |
-165.75 |
-269.13 |
| EPS Diluted |
-2.81 |
-27.97 |
-31.16 |
-40.4 |
-74.91 |
-45.84 |
-65.62 |
-118.21 |
-165.75 |
-269.13 |
| Weighted Average Shares Out |
$1.91 M
|
$278.56 K
|
$261.97 K
|
$223.51 K
|
$177.03 K
|
$154.83 K
|
$115.29 K
|
$103.46 K
|
$64.85 K
|
$45.04 K
|
| Weighted Average Shares Out Diluted |
$1.91 M
|
$278.56 K
|
$261.97 K
|
$223.51 K
|
$177.03 K
|
$154.83 K
|
$115.29 K
|
$103.46 K
|
$64.85 K
|
$45.04 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
